EUVIMEDEUVIMED entdecken
Fallbericht

BRAFV600E ‐Mutant Non‐Langerhans Cell Histiocytosis Clonally Related to Remitted Acute Myeloid Leukemia

Serena Shimshak iD, Liuyan Jiang iD, Olayemi Sokumbi iD

Journal of Cutaneous Pathology · 11.08.2026

DOI: 10.1111/cup.70192 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cutaneous Pathology, online erschienen am 11.08.2026. Verfasst von Serena Shimshak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Mayo Clinic Florida, Jacksonville, Florida, USA. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report a case of a 71‐year‐old female with acute myeloid leukemia (AML), treated with chemotherapy and hematopoietic stem cell transplant (HSCT), who developed a clonally related non‐Langerhans cell histiocytosis (NLCH). She presented with pink papules on the mid‐upper cutaneous lip and thighs 3 months following HSCT. Skin biopsies revealed a dermal proliferation of cells with eosinophilic cytoplasm. Immunohistochemistry (IHC) studies demonstrated positivity for CD68, CD163, BRAF, cyclin D1, and Factor XIIIa and negativity for CD1a, S100, MPO, and CD20. Next‐generation sequencing (NGS) with a comprehensive myeloid panel revealed corresponding pathogenic mutations to her AML, including BCOR Q176fs*40, IDH1 R132C, and TP53 Y163N, and an additional BRAF V600E mutation. Additional mutations in DNMT3A and KMT2A associated with her AML were not identified. These findings supported the diagnosis of NLCH sharing a clonal origin with the patient's AML. Work up demonstrated isolated cutaneous involvement without AML relapse; therefore, the skin lesions were treated with shave excision, topical tacrolimus 0.1% ointment, and topical clobetasol 0.05% cream without further systemic treatment. The acquired BRAF V600E mutation illustrates the potential for divergent myeloid differentiation and likely explains the emergence of a clonal NLCH after successful AML treatment. Genetic analysis in NLCH can establish clonality with associated hematologic malignancies, uncover actionable mutations, and guide treatment.

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukemianext generation sequencingnon‐Langerhans cell histiocytosis

Autor:innen und Institutionen

  • Department of Dermatology, Mayo Clinic Florida, Jacksonville, Florida, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.

ORCID-Profile: Serena Shimshak, Liuyan Jiang, Olayemi Sokumbi

Zitieren

APA

Shimshak, S., Jiang, L., & Sokumbi, O. (2026). BRAFV600E ‐Mutant Non‐Langerhans Cell Histiocytosis Clonally Related to Remitted Acute Myeloid Leukemia. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.70192

Vancouver

Shimshak S, Jiang L, Sokumbi O. BRAFV600E ‐Mutant Non‐Langerhans Cell Histiocytosis Clonally Related to Remitted Acute Myeloid Leukemia. Journal of Cutaneous Pathology. 2026. doi:10.1111/cup.70192

BibTeX
@article{Shimshak2026,
  author = {Shimshak, Serena and Jiang, Liuyan and Sokumbi, Olayemi},
  title = {BRAFV600E ‐Mutant Non‐Langerhans Cell Histiocytosis Clonally Related to Remitted Acute Myeloid Leukemia},
  journal = {Journal of Cutaneous Pathology},
  year = {2026},
  doi = {10.1111/cup.70192}
}
Kostenlos starten →